Third Harmonic Bio, Inc. (THRD)

Market Cap	561.22M
Revenue (ttm)	n/a
Net Income (ttm)	-29.60M
Shares Out	40.76M
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,617
Open	14.58
Previous Close	14.23
Day's Range	13.69 - 14.58
52-Week Range	4.51 - 14.58
Beta	n/a
Analysts	Hold
Price Target	7.00 (-49.51%)
Earnings Date	May 15, 2024

About THRD

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc....

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 15, 2022
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: THRD

Analyst Forecast

According to one analyst, the rating for THRD stock is "Hold" and the 12-month stock price forecast is $7.0.

Price Target

$7.0

(-49.51% downside)

Analyst Consensus: Hold